DGIdb - LINACLOTIDE Drug Record

LINACLOTIDE chembl:CHEMBL3301675 Approved

Alternate Names:

CONSTELLA
LINACLOTIDE
MD-1100
ASP0456
LINZESS
ASP-0456
CYS CYS GLU TYR CYS CYS ASN PRO ALA CYS THR GLY CYS TYR (DISULFIDE BRIDGE: 1-6; 2-10; 5-13)
L-CYSTEINYL-L-CYSTEINYL-L-ALPHA-GLUTAMYL-L-TYROSYL-L-CYSTEINYL-L-CYSTEINYL-L-ASPARAGINYL-L-PROLYL-L-ALANYL-L-CYSTEINYL-L-THREONYLGLYCYL-L-CYSTEINYL-L-TYROSINE CYCLIC (1->6),(2->10),(5->13)-TRIS(DISULFIDE)
chemidplus:851199-59-2
drugbank:08890
pubchem.compound:16158208
chembl:CHEMBL3301675
rxcui:1307404

Drug Info:

FDA Approval	not approved
Drug Class	peptide
Drug Indications	motilitant,for treatment of irritable bowel syndrome

(1 More Sources)

Publications:

Busby et al., 2013, Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation., J. Pharmacol. Exp. Ther.

LINACLOTIDE GUCY2C

Interaction Score: 61.83

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Heat-stable enterotoxin receptor agonist

Direct Interaction yes

Trial Name Linaclotide

PMIDs:
23090647

Sources:
TdgClinicalTrial ChemblInteractions TTD

TdgClinicalTrial: LINACLOTIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications motilitant,for treatment of irritable bowel syndrome

Drug Class peptide

FDA Approval not approved

Publications:
TTD: MD-1100
- Version: 2020.06.01
Alternate Names:

D06WKA TTD Drug ID

Drug Info:

Publications:
TTD: Linaclotide
- Version: 2020.06.01
Alternate Names:

D00GNJ TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL3301675
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3301675
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications: